Abstract
MicroRNAs (miRNAs) are a class of small (18~25 nucleotides long) non-coding RNAs that regulate gene expression on the post-transcriptional level. During the last decade, the field of miRNA research has been exponentially expanding, revealing the widespread role of these molecules in numerous biological processes. Aberrant miRNA expression has been documented in multiple haematologic malignancies, including B cell lymphomas. There is compelling evidence that miRNAs can function as oncogenes or tumor suppressor genes in lymphoid malignancies. In this review, we recapitulate the current knowledge of miRNA expression in B cell malignancies and discuss the accumulating evidence for a major role of miRNA deregulation in the development of B cell-derived lymphoid tumors.
Keywords: B cells, Hodgkin lymphoma, leukemia, lymphoma, MicroRNA.
Current Molecular Medicine
Title:Role of MicroRNAs in B Cell Leukemias and Lymphomas
Volume: 14 Issue: 5
Author(s): A. Schmidt and R. Kuppers
Affiliation:
Keywords: B cells, Hodgkin lymphoma, leukemia, lymphoma, MicroRNA.
Abstract: MicroRNAs (miRNAs) are a class of small (18~25 nucleotides long) non-coding RNAs that regulate gene expression on the post-transcriptional level. During the last decade, the field of miRNA research has been exponentially expanding, revealing the widespread role of these molecules in numerous biological processes. Aberrant miRNA expression has been documented in multiple haematologic malignancies, including B cell lymphomas. There is compelling evidence that miRNAs can function as oncogenes or tumor suppressor genes in lymphoid malignancies. In this review, we recapitulate the current knowledge of miRNA expression in B cell malignancies and discuss the accumulating evidence for a major role of miRNA deregulation in the development of B cell-derived lymphoid tumors.
Export Options
About this article
Cite this article as:
Schmidt A. and Kuppers R., Role of MicroRNAs in B Cell Leukemias and Lymphomas, Current Molecular Medicine 2014; 14 (5) . https://dx.doi.org/10.2174/1566524014666140603095414
DOI https://dx.doi.org/10.2174/1566524014666140603095414 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Rational Drug Design of G-Quartet DNA as Anti-Cancer Agents
Current Pharmaceutical Design Tumor Stem Cell Niches: A New Functional Framework for the Action of Anticancer Drugs
Recent Patents on Anti-Cancer Drug Discovery Ocular Toxicities in Cancer Therapy: Still Overlooked
Current Cancer Therapy Reviews Galectin-9 in Cancer Therapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Non-steroidal Anti-Inflammatory Drugs and Melanoma
Current Pharmaceutical Design Discovery and Design of Peptides as MMP9 Inhibitors through Structure-Based Molecular Docking for Targeted Mantle Cell Lymphoma Therapy
Anti-Cancer Agents in Medicinal Chemistry New Indications for Established Drugs: Combined Tumor-Stroma-Targeted Cancer Therapy with PPARγ Agonists, COX-2 Inhibitors, mTOR Antagonists and Metronomic Chemotherapy
Current Cancer Drug Targets DNA Methylation Leaves Its Mark in Head and Neck Squamous Cell Carcinomas (HNSCC)
Current Genomics Annexin A5 Imaging: An Academic Research – Clinical Trials and Theses
Current Molecular Imaging (Discontinued) Fluorescein-labeled Bacitracin and Daptomycin Conjugates: Synthesis, Fluorescence Imaging and Evaluation
Medicinal Chemistry Animal Models for the Evaluation of Theranostic Radiopharmaceuticals
Current Radiopharmaceuticals 3D-QSAR, Molecular Docking and Molecular Dynamics Studies of 2,4- Diarylaminopyrimidine Analogues (DAAP Analogues) as Potent ALK Inhibitors
Letters in Drug Design & Discovery Glioblastoma Multiforme Imaging: The Role of Nuclear Medicine
Current Radiopharmaceuticals Anticancer Activity of Organogallium(III) Complexes in Colon Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Targeting CD4 to Disrupt Signaling Through Membrane Rafts: Towards a Raft-Based Therapeutics
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Copper Compounds in Anticancer Strategies
Current Medicinal Chemistry Non Polymeric Nanoparticles for Photodynamic Therapy Applications: Recent Developments
Current Medicinal Chemistry Biological Effects of Curcumin and Its Role in Cancer Chemoprevention and Therapy
Anti-Cancer Agents in Medicinal Chemistry Cancer Multitarget Pharmacology in Prostate Tumors: Tyrosine Kinase Inhibitors and Beyond
Current Medicinal Chemistry Evidence of Association between Epstein Barr Virus Serum Antibodies with HAs and RI as Biomarkers of Active Rheumatoid Arthritis
Current Biomarkers (Discontinued)